Yasir Al-Wakeel (Kronos Bio Inc. (Nasdaq: KRON))

Al-Wakeel, Yasir (Kronos Bio 202008– CFO + Head of CorpDev before Neon Therapeutics + Merrimack Pharma + Credit Suisse)

	Organisation	Neon Therapeutics Inc. (Nasdaq: NTGN)
	Today	BioNTech US Inc.
	Group	BioNTech (Group)
	Product	cancer drug
	Product 2	drug development

Kronos Bio, Inc.. (8/19/20). "Press Release: Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development". San Mateo, CA & Cambridge, MA.

Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, today announced the appointment of Yasir Al-Wakeel, BM BCh, as the company’s Chief Financial Officer and Head of Corporate Development.

“Yasir brings a diverse set of capabilities that will be invaluable to us going forward. His strategic finance experience, gleaned from both the corporate finance and research analyst side of Wall Street, operational experience in prior chief financial officer roles, and experience as a practicing clinician, make him an outstanding biopharma executive,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “We are thrilled to have him join the leadership team.”

Dr. Al-Wakeel began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom before his roles in finance and early-stage biotechnology. Prior to Kronos, Dr. Al-Wakeel was Chief Financial and Strategy Officer at Neon Therapeutics, where he played a key role in the company’s public and private financings as well as its eventual sale to BioNTech. Prior to that, he was Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, where he helped shape and execute the company’s refocused business strategy, culminating in a $1 billion asset sale to Ipsen. Before joining Merrimack, Dr. Al-Wakeel served in senior roles in equity research and corporate finance at Credit Suisse focused on the biotechnology sector. During his tenure in corporate finance, he was involved in more than $30 billion in strategic and financial transactions for the firm. Dr. Al-Wakeel received a BM BCh (Doctor of Medicine and Surgery) from Oxford University and an M.A. in theology from Cambridge University.

“Since Kronos’ inception, Norbert and the team have made substantial progress in not only establishing an exciting platform that seeks to unlock historically undruggable oncology targets, but also in establishing a late-stage pipeline with the potential to begin a first registrational trial in 2021,” said Dr. Al-Wakeel. “I am delighted to have the opportunity to work with a leadership team that has been involved in the approval of over 25 novel therapies for the benefit of patients.”

About Kronos Bio, Inc.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.

# # #

Contacts

Investor Contact:
Dr Yasir Al-Wakeel
CFO & Head of Corporate Development
media@kronosbio.com

Media Contact:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

Record changed: 2020-10-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Yasir Al-Wakeel

[1] Kronos Bio, Inc.. (8/19/20). "Press Release: Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development". San Mateo, CA & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)